コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 , are found in patients with Pick's disease (frontotemporal dementia).
2 roach to elucidate the disease mechanisms in frontotemporal dementia.
3 e of its utility in presymptomatic stages of frontotemporal dementia.
4 h as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
5 n cause of amyotrophic lateral sclerosis and frontotemporal dementia.
6 including amyotrophic lateral sclerosis and frontotemporal dementia.
7 ker for the presymptomatic stages of genetic frontotemporal dementia.
8 L over time in the various stages of genetic frontotemporal dementia.
9 patients with amyotrophic lateral sclerosis/frontotemporal dementia.
10 ders amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
11 with presymptomatic and symptomatic genetic frontotemporal dementia.
12 s of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
13 c cause of amyotrophic lateral sclerosis and frontotemporal dementia.
14 neuroinflammation and protein aggregation in frontotemporal dementia.
15 ding amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
16 lusively in social and emotion processing in frontotemporal dementia.
17 S or related TDP-43 proteinopathies, such as frontotemporal dementia.
18 nd the accepted relationship between ALS and frontotemporal dementia.
19 course in a discussion of behavioral variant frontotemporal dementia.
20 ead to multisystem proteinopathies including frontotemporal dementia.
21 including amyotrophic lateral sclerosis and frontotemporal dementia.
22 enic mouse model akin to genetic variants of frontotemporal dementia.
23 atterns of the diverse clinical syndromes of frontotemporal dementia.
24 e impairment (MCI), Alzheimer's disease, and frontotemporal dementia.
25 e diseases amyotrophic lateral sclerosis and frontotemporal dementia.
26 tauopathies, such as Alzheimer's disease and frontotemporal dementia.
27 bule-associated protein tau (MAPT) can cause frontotemporal dementias.
30 hort of 19 patients with behavioural variant frontotemporal dementia, 13 with Alzheimer's disease and
31 istics of family caregivers of patients with frontotemporal dementia, (2) explore the impact of provi
32 th other neurodegenerative diseases (20 with frontotemporal dementia, 20 with Alzheimer's disease, 19
33 ia, are a common autosomal dominant cause of frontotemporal dementia, a neurodegenerative disease com
34 fects, respectively, in clinical subtypes of frontotemporal dementia against neurologically normal co
38 C model of amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD) that recapitulates DNA
39 ived from amyotrophic lateral sclerosis with frontotemporal dementia (ALS/FTD)-associated GGGGCC (G4C
43 tients with TDP-43 proteinopathies (ALS, ALS-frontotemporal dementia [ALS-FTD], and FTLD-TDP-43 [FTLD
44 in amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (ALSFTD-1) have been modified (A
45 d with the spectrum of familial and sporadic frontotemporal dementia-amyotrophic lateral sclerosis (F
47 gnosis of Alzheimer's disease (AD, n = 289), frontotemporal dementia/amyotrophic lateral sclerosis (F
48 tions in VCP cause Paget disease of bone and frontotemporal dementia, an autosomal dominant multisyst
49 h FTLD (15 patients with behavioural variant frontotemporal dementia and 18 with progressive supranuc
50 roup of 25 patients with behavioural variant frontotemporal dementia and 21 control subjects, diagnos
51 non-FTLD donors with a clinical diagnosis of frontotemporal dementia and a different pathological sub
52 in the central nervous system characterizes frontotemporal dementia and ALS in many individuals with
54 n C9orf72, which is the most common cause of frontotemporal dementia and amyotrophic lateral sclerosi
55 amily with autosomal dominant inheritance of frontotemporal dementia and amyotrophic lateral sclerosi
57 autophagy regulation in the pathogenesis of frontotemporal dementia and amyotrophic lateral sclerosi
59 s tauopathies-including Alzheimer's disease, frontotemporal dementia and chronic traumatic encephalop
60 s did not differ between behavioural variant frontotemporal dementia and controls for pleasant or neu
61 oncept of progranulin-boosting therapies for frontotemporal dementia and highlight an important role
62 ch has not been tested in an animal model of frontotemporal dementia and it is unclear if boosting pr
64 ese findings support an overlap between MND, frontotemporal dementia and neuropsychiatric disorders,
65 erebral blood flow shows differences between frontotemporal dementia and other forms of dementia, the
66 72-related amyotrophic lateral sclerosis and frontotemporal dementia and other neurodegenerative dise
67 tiple neurodegenerative disorders, including frontotemporal dementia and parkinsonism linked to chrom
68 ule-associated protein tau), which can cause frontotemporal dementia and parkinsonism linked to chrom
69 ificantly higher risk for clinically defined frontotemporal dementia and progressive supranuclear pal
70 al targets for symptomatic drug treatment of frontotemporal dementia and progressive supranuclear pal
72 s a disease progression biomarker in genetic frontotemporal dementia and suggest that longitudinal Nf
73 selection of trial endpoints for studies in frontotemporal dementia and support the use of neuroimag
74 inclusions are found in 10% of patients with frontotemporal dementia and those with amyotrophic later
75 yndrome shares pathobiological features with frontotemporal dementia and, indeed, many patients show
76 rrying a C9orf72 repeat expansion leading to frontotemporal dementia and/or amyotrophic lateral scler
77 ith at least three other proteins encoded by frontotemporal dementia and/or amyotrophic lateral scler
80 changes are prevalent in behavioural variant frontotemporal dementia, and are associated with changes
81 of APOE and TOMM40 with behavioural variant frontotemporal dementia, and ARHGAP35 and SERPINA1 with
82 rd-seeking behaviours in behavioural variant frontotemporal dementia, and may relate to degeneration
83 in neurons in amyotrophic lateral sclerosis, frontotemporal dementia, and other neurodegenerative dis
88 other neurodegenerative disorders, including frontotemporal dementia (AUC=82.76-100% across cohorts),
90 M106B are thought to modify disease onset in frontotemporal dementia, but its relation to myelination
91 to-insular stroke (FIS), behavioural variant frontotemporal dementia (bvFTD) and Alzheimer's disease
92 l cohort of patients with behavioral variant frontotemporal dementia (bvFTD) and semantic variant pri
94 portion of patients with behavioural variant frontotemporal dementia (bvFTD) develop amyotrophic late
95 lzheimer disease (AD) and behavioral variant frontotemporal dementia (bvFTD) in individual patients b
97 agnosis in patients with behavioural variant frontotemporal dementia (bvFTD) poses a daunting challen
98 were diagnosed with (1) behavioural variant frontotemporal dementia (bvFTD), (2) right temporal vari
99 of the core features of behavioural variant frontotemporal dementia (bvFTD), a neurodegenerative dis
101 on (EF) in patients with behavioural variant frontotemporal dementia (bvFTD), primary progressive aph
102 hat exists between early behavioural variant frontotemporal dementia (bvFTD)--the most common clinica
103 ctural changes in the behavioural variant of frontotemporal dementia (bvFTD); and to correlate cortic
104 rodegenerative disorders: behavioral variant frontotemporal dementia [(bvFTD); n = 35] and Alzheimer'
105 gnostic biomarker in presymptomatic familial frontotemporal dementia', by Jiskoot et al. (doi:10.1093
106 n cause of amyotrophic lateral sclerosis and frontotemporal dementia (C9ALS/FTD), however, the precis
109 associated amyotrophic lateral sclerosis and frontotemporal dementia (C9RAN) and at CGG repeats that
110 iation studies on 3348 clinically identified frontotemporal dementia cases and 9390 controls (discove
111 set of neurodegenerative diseases, including frontotemporal dementia, certain repeat expansion diseas
112 gene cause amyotrophic lateral sclerosis and frontotemporal dementia characterized by dipeptide-repea
113 neurodegenerative disorders, including ALS, frontotemporal dementia, chronic traumatic encephalopath
115 ed resting heart rate in behavioural variant frontotemporal dementia correlated with atrophy involvin
116 odegenerative diseases (Alzheimer's disease, frontotemporal dementia, corticobasal syndrome, and prog
117 rosis and altered motor cortical function in frontotemporal dementia, demonstration of cholinergic de
118 progressive aphasia and behavioural variant frontotemporal dementia differed from controls in the ex
119 cal manifestation of Alzheimer's disease and frontotemporal dementia, diseases characterized by the a
120 Though patients with behavioural variant frontotemporal dementia display changes in their pursuit
121 centre cohort study of families with genetic frontotemporal dementia done across Europe and Canada.
122 le participants (aged >=18 years) either had frontotemporal dementia due to a pathogenic mutation in
124 , we describe two illuminating patients with frontotemporal dementia due to the C9orf72 repeat expans
125 Seventeen patients with behavioural variant frontotemporal dementia [four female; mean (standard dev
126 ]; median age, 62.5 years), 20 patients with frontotemporal dementia (FTD) (8 men [4.5%] and 12 women
127 G(4)C(2)) repeat expansions in C9orf72 cause frontotemporal dementia (FTD) and amyotrophic lateral sc
129 ial function has been found in patients with frontotemporal dementia (FTD) and amyotrophic lateral sc
130 of repeat expansions in the pathogenesis of frontotemporal dementia (FTD) and amyotrophic lateral sc
131 er's disease (AD), Lewy body dementia (LBD), frontotemporal dementia (FTD) and Huntington's disease (
132 ause amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and lead to the production
133 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are age-related neurodegen
134 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are associated with loss o
135 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are neurodegenerative diso
136 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are overlapping neurodegen
137 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are related neurodegenerat
138 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two related neurodegen
139 AD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) as well as in the wild-typ
140 viewed all neuroimaging studies of apathy in frontotemporal dementia (FTD) attempting to refine a neu
141 are similar to Alzheimer's disease (AD) and frontotemporal dementia (FTD) cases, and LSD1 is specifi
145 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) constitute aggressive neur
148 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is a hexanucleotide repeat
157 e in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) presents a significant res
162 with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) susceptibility, and may un
163 G PET studies of Alzheimer dementia (AD) and frontotemporal dementia (FTD) to derive a limit for redu
164 otein aggregation in seven cases of familial frontotemporal dementia (FTD) with mutations in MAPT, GR
167 logical and genetic overlap between sporadic frontotemporal dementia (FTD), Alzheimer's disease (AD)
168 dy dementia (LBD), Parkinson's disease (PD), frontotemporal dementia (FTD), amyotrophic lateral scler
169 disease (PD) and Huntington's disease (HD), frontotemporal dementia (FTD), amyotrophic lateral scler
170 ations in GRN, the gene encoding PGRN, cause frontotemporal dementia (FTD), and a GRN SNP confers sig
171 2 cause amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerati
172 In cross-sectional studies of presymptomatic frontotemporal dementia (FTD), higher education has been
173 s emerging as an early pathological event in frontotemporal dementia (FTD), however biomarkers are la
174 In amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), pathology is often associ
175 arious neurodegenerative diseases, including frontotemporal dementia (FTD), progressive supranuclear
176 ed with AD, P301L mutant tau associated with frontotemporal dementia (FTD), S320F mutant tau associat
177 ding amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), suggesting the hypothesis
178 s implicated in ALS have also been linked to frontotemporal dementia (FTD), suggesting these two dise
179 nts with amyotrophic lateral sclerosis (ALS)/Frontotemporal dementia (FTD), the (G4C2)-RNA repeat exp
183 various neurodegenerative diseases including frontotemporal dementia (FTD), which can be caused by mu
184 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), yet a clear understanding
186 The amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)-linked RNA-binding protein
215 al ALS (fALS), sporadic ALS (sALS), ALS with frontotemporal dementia (FTD-ALS), and Alzheimer's disea
216 Other neurodegenerative diseases, such as frontotemporal dementia (FTD; n = 30), Parkinson's disea
218 allmark of amyotrophic lateral sclerosis and frontotemporal dementia, how aggregates form and what dr
219 s)-Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Huntington's disease, and amyot
220 associated with Paget's disease of bone and frontotemporal dementia (IBM-PFD)-together with its adap
221 inclusion body myopathy, Paget disease with frontotemporal dementia (IBMPFD) and other neurodegenera
222 dy myopathy with Paget's disease of bone and frontotemporal dementia (IBMPFD) that harbor germline mu
223 familial amyotrophic lateral sclerosis (ALS)/frontotemporal dementia in humans through an unknown mec
224 body myopathy, Paget's disease of bone, and frontotemporal dementia in humans unfolds substrate fast
225 E-locus association with behavioural variant frontotemporal dementia indicates its potential risk-inc
226 evalence of amyotrophic lateral sclerosis or frontotemporal dementia, indicating that either genetic
228 hy non-carriers participating in the Genetic Frontotemporal dementia Initiative (GENFI), all of whom
229 from 14 centres collaborating in the Genetic Frontotemporal Dementia Initiative (GENFI), which is a m
230 The current study used data from the Genetic Frontotemporal Dementia Initiative multicentre cohort st
234 ly been established that behavioural variant frontotemporal dementia is associated with abnormal eati
235 om onset and at death of people with genetic frontotemporal dementia is influenced by genetic group a
236 ) and the related neurodegenerative disorder frontotemporal dementia, is the cellular mislocalization
237 ired for transport (ESCRT) machinery, causes frontotemporal dementia linked to chromosome 3 (FTD3).
239 it was hypothesized that behavioural variant frontotemporal dementia might also be associated with al
241 atrophy in presymptomatic carriers of common frontotemporal dementia mutations is affected by both ge
244 oral dementia syndromes: behavioural variant frontotemporal dementia (n = 77) and the semantic (n = 4
245 degeneration, including behavioural variant frontotemporal dementia, non-fluent, and semantic varian
246 PPA while patients with behavioural variant frontotemporal dementia often had semantic impairments.
247 Of 619 subjects with a clinical diagnosis of frontotemporal dementia or primary progressive aphasia,
251 line derived from a C9orf72-HRE positive ALS/frontotemporal dementia patient using CRISPR/Cas9 genome
252 e the role of p25/Cdk5 in tauopathy, we used frontotemporal dementia patient-derived induced pluripot
254 be a modifier of the age at disease onset in frontotemporal dementia patients with TDP-43 pathology.
255 ehavioural symptoms span a range from ALS to frontotemporal dementia, present an opportunity to evalu
256 l expansions in the C9orf72 gene through the Frontotemporal Dementia Prevention Initiative and from p
257 ively unimpaired, mild cognitive impairment, frontotemporal dementia, probable dementia with Lewy bod
258 t spans behavioural and language variants of frontotemporal dementia, progressive supranuclear palsy
259 r treating or preventing such tauopathies as frontotemporal dementia, progressive supranuclear palsy,
260 a with Lewy bodies, multiple system atrophy, frontotemporal dementia, progressive supranuclear palsy,
261 ealed that patients with behavioural variant frontotemporal dementia rated unpleasant odours as less
263 f neuronal progranulin in the development of frontotemporal dementia-related deficits, we generated t
264 ge cohort of presymptomatic subjects bearing frontotemporal dementia-related pathogenic mutations.
265 u linked to familial Parkinson's disease and frontotemporal dementia, respectively, reduced neurite o
267 hometry of patients with behavioural variant frontotemporal dementia revealed that the inability to s
268 dementia (bvFTD), (2) right temporal variant frontotemporal dementia (rtFTD), (3) semantic variant of
269 The concept of the right temporal variant of frontotemporal dementia (rtvFTD) is still equivocal.
270 als, the routine evaluation of patients with frontotemporal dementia should include the presence and
273 nt p.A152T was reported as a risk factor for frontotemporal dementia spectrum and Alzheimer's disease
277 the network involved in eating behaviour in frontotemporal dementia, suggesting a complex interactio
278 oinflammation were associated with different frontotemporal dementia syndromes and supported accurate
279 a cohort of patients representing all major frontotemporal dementia syndromes relative to healthy ag
280 ng of emotional signals is a core feature of frontotemporal dementia syndromes, but the underlying ne
281 gitudinal changes in 161 patients with three frontotemporal dementia syndromes: behavioural variant f
284 models of amyotrophic lateral sclerosis and frontotemporal dementia, that TDP-43 impairs the inducti
285 diseases, including Alzheimer's disease and frontotemporal dementia, the hyperphosphorylation of tau
286 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, though the mechanisms by which
288 lthcare providers who care for patients with frontotemporal dementia to recognize the unique needs of
289 od flow signature of presymptomatic, genetic frontotemporal dementia using a voxel-based approach.
291 europsychiatric International Consortium for Frontotemporal Dementia was recently established to dete
292 stimulus, patients with behavioural variant frontotemporal dementia were less motivated, and therefo
293 allmark of amyotrophic lateral sclerosis and frontotemporal dementia where cytoplasmic TDP-43 inclusi
294 llular accumulation of tau mutants linked to frontotemporal dementia with parkinsonism and alpha-synu
295 ranuclear palsy, eight Pick's disease, three frontotemporal dementia with parkinsonism associated wit
299 L) is a promising blood biomarker in genetic frontotemporal dementia, with elevated concentrations in
300 inning complex socio-emotional phenotypes of frontotemporal dementia, with implications for novel phy